Home > News > pSivida Given a 'Speculative Buy Class A'
March 28th, 2006
pSivida Given a 'Speculative Buy Class A'
Global bio-nanotech drug delivery company, pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) is featured in a report in the March 24, 2006 issue of Bioshares, a respected Australian independent biotech investment newsletter.
Nanometrics Announces Upcoming Investor Events July 28th, 2015
Harris & Harris Group Portfolio Company, Bridgelux, Enters into Agreement to be Acquired by an Investment Group July 22nd, 2015
Harris & Harris Group Portfolio Company, OpGen, Gains $6 Million Investment From Merck GHI in Addition to New Acquisition July 16th, 2015
Harris & Harris Group Portfolio Company, AgBiome, Announces Partnership to Accelerate the Discovery of Next Generation Insect-Resistant Crops July 1st, 2015
Controlling phase changes in solids: Controlling phase changes in solids July 29th, 2015
Perfect Optical Properties in Production of Aluminum Oxide Colloid Nanoparticles July 28th, 2015
Short wavelength plasmons observed in nanotubes: Berkeley Lab researchers create Ludinger liquid plasmons in metallic SWNTs July 28th, 2015
'Seeing' molecular interactions could give boost to organic electronics July 28th, 2015